SHH · 688319.SS
Chengdu Olymvax Biopharmaceuticals Inc.
CN¥26.28+CN¥0.87 (+3.42%)
Chengdu Olymvax Biopharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
Loading market information…
SHH · 605116.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Aurisco Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Aurisco Pharmaceutical Co.,Ltd.’s forward annual dividend is CN¥0.34 per share, paid annual. The forward yield is 1.86% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Aurisco Pharmaceutical Co.,Ltd.’s next earnings report is currently expected on Oct 31, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aurisco Pharmaceutical Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, and chronic obstructive pulmonary disease; eplerenone preparations are used for the treatment of hypertension and heart failure; bepedalic acid preparations are used for the treatment of hypercholesterolemia or atherosclerotic cardiovascular diseases; tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B; pregabalin preparations are used to treat neuropathic pain, fibromyalgia, epilepsy, etc.; brivaracetam preparations are used to treat epilepsy; abiraterone acetate and enzalutamide preparation preparations for the treatment of prostate cancer; and dydrogesterone preparations are used to treat dysmenorrhea, endometriosis, irregular menstrual cycle, etc. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Aug 28, 2024 |
| CN¥0.26 |
| CN¥395.00M0.0% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥26.28+CN¥0.87 (+3.42%)
Chengdu Olymvax Biopharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
CN¥4.93-CN¥0.12 (-2.38%)
Chengzhi Shareholding Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.59% below the high.
CN¥14.98+CN¥1.36 (+9.99%)
Guilin Sanjin Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.89% below the high.
CN¥5.18-CN¥0.09 (-1.71%)
Daan Gene Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.83% below the high.
CN¥41.05-CN¥0.72 (-1.72%)
Chengdu Easton Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.99% below the high.
CN¥47.84+CN¥0.18 (+0.38%)
Chengdu Kanghua Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.69% below the high.
CN¥28.76-CN¥0.24 (-0.83%)
Shanghai Haohai Biological Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.61% below the high.
CN¥7.27+CN¥0.06 (+0.83%)
Zhejiang Ausun Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.75% below the high.
